- £137.09m
- £127.84m
- £32.16m
- 83
- 16
- 55
- 49
Annual balance sheet for Diaceutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 25.3 | 19.7 | 19.8 | 16.7 | 12.7 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 7.78 | 9.92 | 10.4 | 10.1 | 15.7 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 33.6 | 30.1 | 30.9 | 28 | 29.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.238 | 2.13 | 2.09 | 1.9 | 1.68 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 43.5 | 45 | 48.3 | 46.3 | 48.6 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.92 | 2.63 | 3.75 | 4.38 | 7.76 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.28 | 4.36 | 5.74 | 5.56 | 8.76 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 40.2 | 40.6 | 42.5 | 40.8 | 39.9 |
| Total Liabilities & Shareholders' Equity | 43.5 | 45 | 48.3 | 46.3 | 48.6 |
| Total Common Shares Outstanding |